185 related articles for article (PubMed ID: 25881619)
1. Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.
Ganetsky A; Miano TA; Hughes ME; Vonderheide RH; Porter DL; Reshef R
J Antimicrob Chemother; 2015 Jul; 70(7):2078-83. PubMed ID: 25881619
[TBL] [Abstract][Full Text] [Related]
2. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1829-1835. PubMed ID: 27498124
[TBL] [Abstract][Full Text] [Related]
3. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J; Reshef R; Fraser R; Fei M; Abhyankar S; Al-Kadhimi Z; Alousi AM; Antin JH; Arai S; Bickett K; Chen YB; Damon LE; Efebera YA; Geller NL; Giralt SA; Hari P; Holtan SG; Horowitz MM; Jacobsohn DA; Jones RJ; Liesveld JL; Logan BR; MacMillan ML; Mielcarek M; Noel P; Pidala J; Porter DL; Pusic I; Sobecks R; Solomon SR; Weisdorf DJ; Wu J; Pasquini MC; Koreth J
Lancet Haematol; 2019 Mar; 6(3):e132-e143. PubMed ID: 30824040
[TBL] [Abstract][Full Text] [Related]
4. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
Reshef R; Luger SM; Hexner EO; Loren AW; Frey NV; Nasta SD; Goldstein SC; Stadtmauer EA; Smith J; Bailey S; Mick R; Heitjan DF; Emerson SG; Hoxie JA; Vonderheide RH; Porter DL
N Engl J Med; 2012 Jul; 367(2):135-45. PubMed ID: 22784116
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.
Dufty NE; Gilleran G; Hawkins D; Else LJ; Taylor S
J Antimicrob Chemother; 2013 Apr; 68(4):972-4. PubMed ID: 23249840
[No Abstract] [Full Text] [Related]
7. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation.
Collins J; Shea K; Parsad S; Plach K; Lee P
J Oncol Pharm Pract; 2020 Jan; 26(1):5-12. PubMed ID: 30854922
[TBL] [Abstract][Full Text] [Related]
8. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc: pharmacokinetics and drug interactions.
Abel S; Back DJ; Vourvahis M
Antivir Ther; 2009; 14(5):607-18. PubMed ID: 19704163
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
11. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
[TBL] [Abstract][Full Text] [Related]
12. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Garvey L; Nelson M; Latch N; Erlwein OW; Allsop JM; Mitchell A; Kaye S; Watson V; Back D; Taylor-Robinson SD; Winston A
J Antimicrob Chemother; 2012 Jan; 67(1):206-12. PubMed ID: 21987241
[TBL] [Abstract][Full Text] [Related]
13. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Zhu J; Patel T; Miller JA; Torrice CD; Aggarwal M; Sketch MR; Alexander MD; Armistead PM; Coghill JM; Grgic T; Jamieson KJ; Ptachcinski JR; Riches ML; Serody JS; Schmitz JL; Shaw JR; Shea TC; Suzuki O; Vincent BG; Wood WA; Rao KV; Wiltshire T; Weimer ET; Crona DJ
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013193
[TBL] [Abstract][Full Text] [Related]
14. [Clinical pharmacokinetic of maraviroc].
Peytavin G
Med Mal Infect; 2008 Mar; 38 Suppl 1():S12-6. PubMed ID: 18455057
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.
Moy RH; Huffman AP; Richman LP; Crisalli L; Wang XK; Hoxie JA; Mick R; Emerson SG; Zhang Y; Vonderheide RH; Porter DL; Reshef R
Blood; 2017 Feb; 129(7):906-916. PubMed ID: 28057639
[TBL] [Abstract][Full Text] [Related]
16. Impact of
Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
[TBL] [Abstract][Full Text] [Related]
17. Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
Reshef R; Ganetsky A; Acosta EP; Blauser R; Crisalli L; McGraw J; Frey NV; Hexner EO; Hoxie JA; Loren AW; Luger SM; Mangan J; Stadtmauer EA; Mick R; Vonderheide RH; Porter DL
Biol Blood Marrow Transplant; 2019 Mar; 25(3):515-521. PubMed ID: 30315941
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus in adult hematopoietic stem cell transplantation.
Gao Y; Ma J
Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):803-811. PubMed ID: 31595800
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
Ramanathan S; Abel S; Tweedy S; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Feb; 53(2):209-14. PubMed ID: 19851115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
